Frédéric Michel Lamoth

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


76 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
 
Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.
Duss F.R., Garcia de la Mària C., Croxatto A., Giulieri S., Lamoth F., Manuel O., Miró J.M., 2019/09/01. The Journal of antimicrobial chemotherapy, 74 (9) pp. 2626-2630. Peer-reviewed.
 
Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.
Aruanno M., Glampedakis E., Lamoth F., 2019/08. Antimicrobial agents and chemotherapy, 63 (8). Peer-reviewed.
Link between Heat Shock Protein 90 and the Mitochondrial Respiratory Chain in the Caspofungin Stress Response of Aspergillus fumigatus.
Aruanno M., Bachmann D., Sanglard D., Lamoth F., 2019/07. Antimicrobial agents and chemotherapy, 63 (7) pp. e00208-19.. Peer-reviewed.
 
Isavuconazole brain penetration in cerebral aspergillosis.
Lamoth F., Mercier T., André P., Pagani J.L., Pantet O., Maduri R., Guery B., Decosterd L.A., 2019/06/01. The Journal of antimicrobial chemotherapy, 74 (6) pp. 1751-1753. Peer-reviewed.
 
Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project.
Bassetti M., Scudeller L., Giacobbe D.R., Lamoth F., Righi E., Zuccaro V., Grecchi C., Rebuffi C., Akova M., Alastruey-Izquierdo A. et al., 2019/04. Mycoses, 62 (4) pp. 310-319. Peer-reviewed.
 
Diagnostic approach to encephalitis and meningoencephalitis in adult returning travellers.
Kenfak A., Eperon G., Schibler M., Lamoth F., Vargas M.I., Stahl J.P., 2019/04. Clinical microbiology and infection, 25 (4) pp. 415-421. Peer-reviewed.
 
Diagnosis and treatment of invasive fungal infections: looking ahead.
Sanguinetti M., Posteraro B., Beigelman-Aubry C., Lamoth F., Dunet V., Slavin M., Richardson M.D., 2019/03/01. The Journal of antimicrobial chemotherapy, 74 (Supplement_2) pp. ii27-ii37. Peer-reviewed.
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
 
Efficacy of Antifungal Monotherapies and Combinations against Aspergillus calidoustus.
Glampedakis E., Coste A.T., Aruanno M., Bachmann D., Delarze E., Erard V., Lamoth F., 2018/12. Antimicrobial agents and chemotherapy, 62 (12). Peer-reviewed.
 
Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A., Neofytos D., Khanna N., Schreiber P.W., Boggian K., Bille J., Schrenzel J., Mühlethaler K., Zbinden R., Bruderer T. et al., 2018/11. Clinical microbiology and infection, 24 (11) pp. 1214.e1-1214.e4. Peer-reviewed.
 
Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.
Brunel A.S., Wójtowicz A., Lamoth F., Spertini O., Neofytos D., Calandra T., Marchetti O., Bochud P.Y., 2018/11. Haematologica, 103 (11) pp. e527-e530. Peer-reviewed.
 
Let's add invasive aspergillosis to the list of influenza complications.
Lamoth F., Calandra T., 2018/10. The Lancet. Respiratory medicine, 6 (10) pp. 733-735. Peer-reviewed.
 
Role of bi-weekly serum galactomannan screening for the diagnosis of invasive aspergillosis in haematological cancer patients.
Couchepin J., Brunel A.S., Jaton K., Meylan P., Bochud P.Y., Lamoth F., 2018/06. Mycoses, 61 (6) pp. 350-354. Peer-reviewed.
 
Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study.
Orasch C., Mertz D., Garbino J., van Delden C., Emonet S., Schrenzel J., Zimmerli S., Damonti L., Mühlethaler K., Imhof A. et al., 2018/05. The Journal of infection, 76 (5) pp. 489-495. Peer-reviewed.
 
Correction to: Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia.
Damonti L., Erard V., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Imhof A., Zbinden R., Fehr J., Boggian K. et al., 2018/03..
 
The Candida auris Alert: Facts and Perspectives.
Lamoth F., Kontoyiannis D.P., 2018/01/30. The Journal of infectious diseases, 217 (4) pp. 516-520. Peer-reviewed.
 
Changes in the epidemiological landscape of invasive candidiasis.
Lamoth F., Lockhart S.R., Berkow E.L., Calandra T., 2018/01/01. The Journal of antimicrobial chemotherapy, 73 (suppl_1) pp. i4-i13. Peer-reviewed.
First case of Candida auris in Switzerland: discussion about preventive strategies.
Riat A., Neofytos D., Coste A., Harbarth S., Bizzini A., Grandbastien B., Pugin J., Lamoth F., 2018. Swiss medical weekly, 148 pp. w14622. Peer-reviewed.
 
Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia.
Damonti L., Erard V., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Imhof A., Zbinden R., Fehr J., Boggian K. et al., 2017/06. Intensive care medicine, 43 (6) pp. 935-939. Peer-reviewed.
 
Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis.
Lamoth F., Chung S.J., Damonti L., Alexander B.D., 2017/06/01. Clinical infectious diseases, 64 (11) pp. 1619-1621. Peer-reviewed.
 
Early diagnosis of invasive mould infections and disease.
Lamoth F., Calandra T., 2017/03/01. The Journal of antimicrobial chemotherapy, 72 (suppl_1) pp. i19-i28. Peer-reviewed.
 
Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.
Lamoth F., Damonti L., Alexander B.D., 2016/06. Journal of clinical microbiology, 54 (6) pp. 1638-1640. Peer-reviewed.
 
Aspergillus fumigatus-Related Species in Clinical Practice.
Lamoth F., 2016. Frontiers in microbiology, 7 p. 683. Peer-reviewed.
 
Editorial: Advances in Aspergillus fumigatus Pathobiology.
Lamoth F., Juvvadi P.R., Steinbach W.J., 2016. Frontiers in microbiology, 7 p. 43. Peer-reviewed.
Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis
Lamoth Frédéric, 2016. Journal of Fungi, 2 (3) p. 22.
 
Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus.
Lamoth F., Juvvadi P.R., Steinbach W.J., 2016. Critical reviews in microbiology, 42 (2) pp. 310-321. Peer-reviewed.
 
Potential Microbiological Effects of Higher Dosing of Echinocandins.
Steinbach W.J., Lamoth F., Juvvadi P.R., 2015/12/01. Clinical infectious diseases, 61 Suppl 6 pp. S669-77. Peer-reviewed.
 
Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds.
Lamoth F., Alexander B.D., 2015/10. Journal of clinical microbiology, 53 (10) pp. 3176-3181. Peer-reviewed.
 
Calcium-Mediated Induction of Paradoxical Growth following Caspofungin Treatment Is Associated with Calcineurin Activation and Phosphorylation in Aspergillus fumigatus.
Juvvadi P.R., Muñoz A., Lamoth F., Soderblom E.J., Moseley M.A., Read N.D., Steinbach W.J., 2015/08. Antimicrobial agents and chemotherapy, 59 (8) pp. 4946-4955. Peer-reviewed.
 
Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus.
Lamoth F., Juvvadi P.R., Soderblom E.J., Moseley M.A., Steinbach W.J., 2015/08. Antimicrobial agents and chemotherapy, 59 (8) pp. 4727-4733. Peer-reviewed.
 
The Aspergillus fumigatus septins play pleiotropic roles in septation, conidiation, and cell wall stress, but are dispensable for virulence.
Vargas-Muñiz J.M., Renshaw H., Richards A.D., Lamoth F., Soderblom E.J., Moseley M.A., Juvvadi P.R., Steinbach W.J., 2015/08. Fungal genetics and biology, 81 pp. 41-51. Peer-reviewed.
 
Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.
Lamoth F., Alexander B.D., 2015/07. Antimicrobial agents and chemotherapy, 59 (7) pp. 4308-4311. Peer-reviewed.
 
Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species.
Lamoth F., Alexander B.D., Juvvadi P.R., Steinbach W.J., 2015/05. The Journal of antimicrobial chemotherapy, 70 (5) pp. 1408-1411. Peer-reviewed.
 
Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis.
Lamoth F., Juvvadi P.R., Steinbach W.J., 2015. Frontiers in microbiology, 6 p. 96. Peer-reviewed.
 
Identification and mutational analyses of phosphorylation sites of the calcineurin-binding protein CbpA and the identification of domains required for calcineurin binding in Aspergillus fumigatus.
Juvvadi P.R., Ma Y., Richards A.D., Soderblom E.J., Moseley M.A., Lamoth F., Steinbach W.J., 2015. Frontiers in microbiology, 6 p. 175. Peer-reviewed.
 
Waddlia: An emerging pathogen and a model organism to study the biology of chlamydiae.
Lamoth F., Pillonel T., Greub G., 2015. Microbes and infection, 17 (11-12) pp. 732-737. Peer-reviewed.
 
Calcineurin-mediated regulation of hyphal growth, septation, and virulence in Aspergillus fumigatus.
Juvvadi P.R., Lamoth F., Steinbach W.J., 2014/12. Mycopathologia, 178 (5-6) pp. 341-348. Peer-reviewed.
 
Approches diagnostiques des bactéries intracellulaires et des germes fastidieux [Diagnostic approach of intracellular bacteria and fastidious microorganisms]
Lamoth F., Schrenzel J., Greub G., 2014/11/12. Revue medicale suisse, 10 (450) pp. 2130-2136. Peer-reviewed.
 
Nonmolecular methods for the diagnosis of respiratory fungal infections.
Lamoth F., Alexander B.D., 2014/06. Clinics in laboratory medicine, 34 (2) pp. 315-336. Peer-reviewed.
 
Polymorphisms in tumor necrosis factor-α increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients*.
Wójtowicz A., Tissot F., Lamoth F., Orasch C., Eggimann P., Siegemund M., Zimmerli S., Flueckiger U.M., Bille J., Calandra T. et al., 2014/04. Critical care medicine, 42 (4) pp. e304-8. Peer-reviewed.
 
Heat Shock Protein 90 (Hsp90) in Fungal Growth and Pathogenesis
Lamoth Frédéric, Juvvadi Praveen R., Steinbach William J., 2014. Current Fungal Infection Reports, 8 (4) pp. 296-301.
 
Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus.
Lamoth F., Juvvadi P.R., Soderblom E.J., Moseley M.A., Asfaw Y.G., Steinbach W.J., 2014. Antimicrobial agents and chemotherapy, 58 (4) pp. 1889-1896. Peer-reviewed.
 
Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus.
Lamoth F., Juvvadi P.R., Gehrke C., Asfaw Y.G., Steinbach W.J., 2014. Journal of Infectious Diseases, 209 (3) pp. 473-481.
 
β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis.
Tissot F., Lamoth F., Hauser P.M., Orasch C., Flückiger U., Siegemund M., Zimmerli S., Calandra T., Bille J., Eggimann P. et al., 2013/11/01. American journal of respiratory and critical care medicine, 188 (9) pp. 1100-1109. Peer-reviewed.
 
In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains.
Lamoth F., Juvvadi P.R., Gehrke C., Steinbach W.J., 2013. Antimicrobial Agents and Chemotherapy, 57 (2) pp. 1035-1039.
Phosphorylation of Calcineurin at a novel serine-proline rich region orchestrates hyphal growth and virulence in Aspergillus fumigatus.
Juvvadi P.R., Gehrke C., Fortwendel J.R., Lamoth F., Soderblom E.J., Cook E.C., Hast M.A., Asfaw Y.G., Moseley M.A., Creamer T.P. et al., 2013. Plos Pathogens, 9 (8) pp. e1003564.
 
Phosphorylation of Calcineurin at a novel serine-proline rich region orchestrates hyphal growth and virulence in Aspergillus fumigatus.
Juvvadi P.R., Gehrke C., Fortwendel J.R., Lamoth F., Soderblom E.J., Cook E.C., Hast M.A., Asfaw Y.G., Moseley M.A., Creamer T.P. et al., 2013. PLoS pathogens, 9 (8) pp. e1003564. Peer-reviewed.
 
ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients.
Marchetti O., Lamoth F., Mikulska M., Viscoli C., Verweij P., Bretagne S., European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups, 2012/06. Bone marrow transplantation, 47 (6) pp. 846-854. Peer-reviewed.
 
β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3).
Lamoth F., Cruciani M., Mengoli C., Castagnola E., Lortholary O., Richardson M., Marchetti O., Third European Conference on Infections in Leukemia (ECIL-3), 2012/03/01. Clinical infectious diseases, 54 (5) pp. 633-643. Peer-reviewed.
 
Heat shock protein 90 is required for conidiation and cell wall integrity in Aspergillus fumigatus.
Lamoth F., Juvvadi P.R., Fortwendel J.R., Steinbach W.J., 2012. Eukaryotic Cell, 11 (11) pp. 1324-1332.
 
Parachlamydia and Rhabdochlamydia: emerging agents of community-acquired respiratory infections in children.
Lamoth F., Jaton K., Vaudaux B., Greub G., 2011/09. Clinical infectious diseases, 53 (5) pp. 500-501. Peer-reviewed.
 
Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever?
Robinson J.O., Lamoth F., Bally F., Knaup M., Calandra T., Marchetti O., 2011/04/25. PloS one, 6 (4) pp. e18886. Peer-reviewed.
 
Immunogenetics of invasive aspergillosis.
Lamoth F., Rubino I., Bochud P.Y., 2011/04. Medical mycology, 49 Suppl 1 pp. S125-36. Peer-reviewed.
 
Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.
Rochat B., Pascual A., Pesse B., Lamoth F., Sanglard D., Decosterd L.A., Bille J., Marchetti O., 2010/12. Antimicrobial agents and chemotherapy, 54 (12) pp. 5074-5081. Peer-reviewed.
 
High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.
Lamoth F., Buclin T., Pascual A., Vora S., Bolay S., Decosterd L.A., Calandra T., Marchetti O., 2010/10. Antimicrobial agents and chemotherapy, 54 (10) pp. 4360-4367. Peer-reviewed.
 
Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia.
Lamoth F., Jaton K., Prod'hom G., Senn L., Bille J., Calandra T., Marchetti O., 2010/10. Journal of clinical microbiology, 48 (10) pp. 3510-3516. Peer-reviewed.
 
Comparison of hospital-wide and unit-specific cumulative antibiograms in hospital- and community-acquired infection.
Lamoth F., Wenger A., Prod'hom G., Vallet Y., Plüss-Suard C., Bille J., Zanetti G., 2010/08. Infection, 38 (4) pp. 249-253. Peer-reviewed.
 
Fastidious intracellular bacteria as causal agents of community-acquired pneumonia.
Lamoth F., Greub G., 2010/07. Expert review of anti-infective therapy, 8 (7) pp. 775-790. Peer-reviewed.
 
Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection.
Lebeau O., Van Delden C., Garbino J., Robert J., Lamoth F., Passweg J., Chalandon Y., 2010/06. Transplant infectious disease, 12 (3) pp. 269-272. Peer-reviewed.
 
Amoebal pathogens as emerging causal agents of pneumonia.
Lamoth F., Greub G., 2010/05. FEMS microbiology reviews, 34 (3) pp. 260-280. Peer-reviewed.
 
Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet N., Manuel O., Lamoth F., Venetz J.P., Sahli R., Decosterd L.A., Buclin T., Pascual M., Meylan P., 2010/01/06. BMC infectious diseases, 10 p. 2. Peer-reviewed.
 
Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study.
Manuel O., Pascual M., Perrottet N., Lamoth F., Venetz J.P., Decosterd L.A., Buclin T., Meylan P.R., 2010. Clinical transplantation, 24 (6) pp. 794-800. Peer-reviewed.
 
Parachlamydia and rhabdochlamydia in premature neonates.
Lamoth F., Aeby S., Schneider A., Jaton-Ogay K., Vaudaux B., Greub G., 2009/12. Emerging infectious diseases, 15 (12) pp. 2072-2075. Peer-reviewed.
 
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction.
Lamoth F., Erard V., Asner S., Buclin T., Calandra T., Marchetti O., 2009/10. International journal of antimicrobial agents, 34 (4) pp. 386-388. Peer-reviewed.
 
Imipenem underdosing as a cause of persistent neutropenic fever?
Lamoth F., Buclin T., Pascual A., Calandra T., Marchetti O., 2009/09. The Journal of antimicrobial chemotherapy, 64 (3) pp. 665-667. Peer-reviewed.
 
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N., Csajka C., Pascual M., Manuel O., Lamoth F., Meylan P., Aubert J.D., Venetz J.P., Soccal P., Decosterd L.A. et al., 2009/07. Antimicrobial agents and chemotherapy, 53 (7) pp. 3017-3023. Peer-reviewed.
 
On track to limit antifungal overuse!
Eggimann P., Lamoth F., Marchetti O., 2009/04. Intensive care medicine, 35 (4) pp. 582-584. Peer-reviewed.
 
Aspergillose invasive : perspectives en infectiologie préventive [Preventing invasive aspergillosis in hematopoietic stem cells transplant recipients]
Lamoth F., Bochud P.Y., 2009. Medecine sciences, 25 (8-9) pp. 669-672. Peer-reviewed.
 
Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
Lamoth F., Buclin T., Csajka C., Pascual A., Calandra T., Marchetti O., 2009. Antimicrobial Agents and Chemotherapy, 53 (2) pp. 785-787. Peer-reviewed.
 
Case report: human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient.
Lamoth F., Jayet P.Y., Aubert J.D., Rotman S., Mottet C., Sahli R., Lautenschlager I., Pascual M., Meylan P., 2008/10. Journal of medical virology, 80 (10) pp. 1804-1807. Peer-reviewed.
 
Case report: human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient.
Lamoth F., Jayet P.Y., Aubert J.D., Rotman S., Mottet C., Sahli R., Lautenschlager I., Pascual M., Meylan P., 2008. Journal of Medical Virology, 80 (10) pp. 1804-1807.
 
Cytomegalovirus infection and new-onset post-transplant diabetes mellitus.
Leung Ki E.L., Venetz J.P., Meylan P., Lamoth F., Ruiz J., Pascual M., 2008. Clinical transplantation, 22 (2) pp. 245-249. Peer-reviewed.
 
Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature.
Lamoth F., Pascual M., Erard V., Venetz J.P., Nseir G., Meylan P., 2008. Antiviral therapy, 13 (8) pp. 1001-1009. Peer-reviewed.
 
What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation?
Lamoth F., Manuel O., Venetz J.P., Faouzi M., Meylan P., Pascual M., 2008. Transplantation, 86 (9) pp. 1323-1324.
Blood samples drawn for culture as a surrogate marker for case-mix adjustment of hospital antibiotic use.
Lamoth F., Francioli P., Zanetti G., 2007/04. Clinical Microbiology and Infection, 13 (4) pp. 454-456. Peer-reviewed.
 
Etat fébrile et Hépatosplénomégalie chez une femme de 25 ans: approche diagnostique [A 25-year-old woman with fever and hepatosplenomegaly: diagnostic approach]
Lamoth F., Chabanel D., Waeber G., 2006/07/05. Praxis, 95 (27-28) pp. 1081-1084. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University